Replies to post #145560 on Biotech Values

[vinmantoo]

Peter,

How does the Ponatinib data stack up to the recent data for Regorafenib in GIST patients whose disease has progressed after both Gleevec and Sutent? Here is a link to the Regorafenib data.

http://www.prnewswire.com/news-releases/phase-3-data-on-regorafenib-met-primary-endpoint-showing-significant-improvement-in-progression-free-survival-in-patients-with-gist-156933895.html